MMP9 and systemic sclerosis: WYHZTL formula promoted MMP-9 secretion, inhibited TIMP-1 production, regulated MMP-9/TIMP-1 imbalance, and reduced the serum PIIINP levels while upregulated ICTP levels in SSc patients, thereby reducing fibrosis [31].